Open AccessDurable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
Author(s) -
Elhassadi Ezzat,
Murphy Maurice,
Hacking Dayle,
Farrell Michael
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1451
Subject(s) - medicine , daratumumab , radiation therapy , chemotherapy , multiple myeloma , plasmacytoma , oncology , complication , disease , surgery , bortezomib
Key Clinical Message CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation.